p3

Cambridge Healthtech Institute’s 7th Annual

Antibody-Drug Conjugates
( 抗体药物复合体 )

Next-Gen Engineering

1月21日~22日

Part of the Antibody Therapeutics pipeline

Antibody-Drug Conjugates have demonstrated their ability to deliver cytotoxic small-molecule drugs through a selective and targeted mechanism in the fight against cancer. In recent years, ADCs have entered almost 600 clinical trials with more than 60 distinct ADC molecules currently under development. Despite the enormous promise, a low therapeutic index has plagued ADC development, particularly for treating solid tumors.

Cambridge Healthtech Institute’s Antibody-Drug Conjugates conference explores the engineering finesse required to achieve the crucial balance between efficacy and safety, thus leading the way to more potent and targeted molecules. Case studies and data will be shared that illustrate the ongoing efforts to engineer ADCs, move them into the clinic, and conquer cancer.

Preliminary Agenda

ADCs FOR IMMUNOTHERAPY: A WINDING PATH

KEYNOTE PRESENTATION: Learnings from Successes and Failures of ADCs and Cancer Immunotherapies

Rakesh Dixit, PhD, DABT, President & CEO, Bionavigen, LLC

Antibody-Drug Conjugates for Immunology (iADC)

Adrian Hobson, PhD, Research Fellow, Global Biologics - Antibody Drug Conjugates, AbbVie Bioresearch Center, AbbVie

NAVIGATING THE PROMISE OF ADCs

Antibody-Drug Conjugates: Progress, Pitfalls, and Promises

Mark Glassy, PhD, Chairman, Nascent Biotech, Inc.

Antibody-Drug Conjugates as Targeted Conditioning Agents for Bone Marrow Transplant Patients

Bradley Pearse, PhD, Director, Biotherapeutics, Magenta Therapeutics

TARGETING TUMORS WITH ADCs

Improved Tumor Growth Inhibition of Diabody-Drug Conjugates Achieved by Half-Life Extension

Qing Li, PhD, Scientist, Antibody Discovery & Protein Engineering, AstraZeneca plc

Optimal Design, Anti-Tumor Efficacy, and Tolerability of Anti-CXCR4 Antibody-Drug Conjugates

Maria J. Costa, PhD, Associate Director, Research, Immune Onc Therapeutics, Inc.

INNOVATING ADC ENGINEERING

Probody Therapeutics in the Treatment of Cancer

Siew Schleyer, PhD, Director, Oncology Research, Cytomx Therapeutics

Amanitin-Based Antibody-Drug Conjugates as New Therapeutic Modalities for Cancer Therapy

George Octavian Badescu, PhD, Vice President, Scientific Affairs, Heidelberg Pharma AG

Peptide Nucleic Acid (PNA)-Mediated Pretargeting for Radionuclide Therapy

Amelie Eriksson Karlström, PhD, Professor, Protein Sciences, Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology



* 活动内容有可能不事先告知作更动及调整。

Choose your language
Chinese
Japanese
Korean
English






2020年会议节目和培训研讨会


免费电子邮件通知服务